vimarsana.com
Home
Live Updates
Transcenta to Present "Trial in Progress" at ASCO-GI 2023 fo
Transcenta to Present "Trial in Progress" at ASCO-GI 2023 fo
Transcenta to Present "Trial in Progress" at ASCO-GI 2023 for TST001 (Osemitamab) Combination with Nivolumab, with or without Chemotherapy in Advanced G/GEJ Cancer
/PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in...
Related Keywords
China ,
Guangzhou ,
Guangdong ,
Shanghai ,
Suzhou ,
Jiangsu ,
Boston ,
Massachusetts ,
United States ,
Beijing ,
Princeton ,
Hangzhou ,
Zhejiang ,
Los Angeles ,
Caroline Germa ,
Weijian Guo ,
Transcenta Holding ,
Product Development Center ,
Clinical Development Centers In Princeton ,
Translational Research Center ,
Group Headquarters ,
Prnewswire Transcenta Holding Limited ,
Fudan University Shanghai Cancer Center ,
Global Medicine Development ,
Transcenta Immune Tolerance Breaking Technology ,
Holding Limited ,
High Affinity Humanized Anti Claudin ,
Late Line Treatment ,
Locally Advanced ,
Gastroesophageal Junction ,
Progress Poster Session ,
Professor Weijian Guo ,
Fudan University Shanghai Cancer ,
Executive Vice President ,
Chief Medical ,
Immune Tolerance Breaking Technology ,
Orphan Drug Designation ,
Manufacturing Facility ,
Clinical Development Centers ,
External Partnering Center ,
Suzhou Industrial ,
Transcenta Holding Limited ,